References

(in order of presentation)

Novel chemical space exploration via natural products.
Rosén J, Gottfries J, Muresan S, Backlund A, Oprea TI.
J Med Chem. 2009 Apr 9;52(7):1953-62.

The impact of natural products upon modern drug discovery.
Ganesan A.
Curr Opin Chem Biol. 2008 Jun;12(3):306-17.

The druggable genome.
Hopkins AL, Groom CR.
Nat Rev Drug Discov. 2002 Sep;1(9):727-30.

Mutasynthesis of rapamycin analogues through the manipulation of a gene governing starter unit biosynthesis.
Gregory MA, Petkovic H, Lill RE, Moss SJ, Wilkinson B, Gaisser S, Leadlay PF, Sheridan RM.
Angew Chem Int Ed Engl. 2005 Jul 25;44(30):4757-60.

Rapamycin biosynthesis: Elucidation of gene product function.
Gregory MA, Hong H, Lill RE, Gaisser S, Petkovic H, Low L, Sheehan LS, Carletti I, Ready SJ, Ward MJ, Kaja AL, Weston AJ, Challis IR, Leadlay PF, Martin CJ, Wilkinson B, Sheridan RM.
Org Biomol Chem. 2006 Oct 7;4(19):3565-8.

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.
Sehgal SN, Baker H, Vézina C.
J Antibiot (Tokyo). 1975 Oct;28(10):727-32.

Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP.
Choi J, Chen J, Schreiber SL, Clardy J.
Science. 1996 Jul 12;273(5272):239-42.

Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons.
Bishop KM, Hofer EK, Mehta A, Ramirez A, Sun L, Tuszynski M, Bartus RT.
Exp Neurol. 2008 Jun;211(2):574-84.

'Rejuvenation' protects neurons in mouse models of Parkinson's disease.
Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, Meredith GE, Surmeier DJ.
Nature. 2007 Jun 28;447(7148):1081-6.

Use of antihypertensives and the risk of Parkinson disease.
Becker C, Jick SS, Meier CR.
Neurology. 2008 Apr 15;70(16 Pt 2):1438-44.

L-type calcium channel blockers and Parkinson disease in Denmark.
Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S.
Ann Neurol. 2010 May;67(5):600-6.

Neurotrophic Factor Mimetics: Target Validation to Lead Optimization >